Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584896 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease
A Phase 3 study, sponsored by Point Biomedical.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT00584896 is a Phase 3 study that was terminated before completion, run by Point Biomedical. The registered enrollment target is 1,000 participants.
The verdict
NCT00584896, a Phase 3 study, was terminated before completion, sponsored by Point Biomedical.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of PB127 with cardiac ultrasound assists in the diagnosis or exclusion of coronary artery disease.
Interventions
- DRUG PB127 for Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584896
The ClinicalTrials.gov registry entry for NCT00584896 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Point Biomedical, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PB127 for Injectable Suspension is the first listed.
NCT00584896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00584896 about?
NCT00584896 is a clinical study titled "Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease". The purpose of this study is to determine if the use of PB127 with cardiac ultrasound assists in the diagnosis or exclusion of coronary artery disease.
What is the current status of trial NCT00584896?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2007-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00584896?
The interventions under investigation include: PB127 for Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT00584896?
This trial is sponsored by Point Biomedical, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.